Lilly presented full phase 3 TRIUMPH-2 data for retatrutide at the EASD meeting in Milan. Dr. Tafari calls the results groundbreaking, though no figures are given.
Recap by typeshit. Post by @dr_tafari on Instagram.
A Facebook post says US researchers found pancreatic cells producing GLP-1 on their own. It frames this as a possible built-in appetite and sugar control system, without naming the study.
Researchers are studying whether GLP-1 drugs, which act on mood, appetite and reward pathways, could help with depression, addiction and binge eating.
A retrospective cohort checks whether retinal disease started or worsened more in established users than in people never on either drug, plus a regional NAION review.
24:34
An animated explainer walking through what semaglutide does in the body, from appetite signals in the brain to digestion and blood sugar control.
A hype-heavy explainer on retatrutide, the Lilly drug that targets three hormone pathways at once. It doesn't add anything new on trials or approval timing.
Gallup puts US adult GLP-1 use at 11%. PepsiCo and Hershey shares are down over the past year, though Hershey's breath mint sales are growing.
Loading…